Resources
Production of recombinant protein with <em>E. coli</em>
While E. coli remains crucial for plasmid DNA production, demand for innovations is growing, particularly for genetic medicines like gene therapies and RNA therapeutics. Novel approaches, including alternative production methods, are being explored to address the challenges of cost, scalability, and efficiency in plasmid manufacturing.
How <em>E. coli</em> cemented its place in the biotech industry
E. coli revolutionized biotech in 1973 when researchers developed recombinant DNA technology, enabling scientists to clone genes in bacteria. Today, E. coli remains central to DNA cloning, but modern challenges—like the need for larger, more complex plasmids—are pushing this 50-year-old technology to its limits.
Challenges and opportunities in plasmid DNA production
Plasmid DNA is crucial for gene therapy, RNA therapeutics, and vaccine production, but current manufacturing methods face challenges with yield, speed, and stability. Demand is growing for more reliable and scalable platforms for both research and clinical-scale plasmid production.
